APRI, FIB4, and Fibroscan as Predictors of early Hepatocellular Carcinoma Recurrence in patients underwent Thermal Ablation

Authors

Magdy Abd-Alkareem Al-Dahshan, Professor and Head of Internal Medicine Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
Amin Abdel Baki, Professor and Head of Gastroenterology and Hepatology Department, National Hepatology and Tropical Medicine Research Institute, Al-Azhar University, Cairo, Egypt
Ibrahim Ghouniem Ramadan, Assistant Professor of Internal Medicine, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
Sherif Farouk Aly, Assistant Professor and Consultant of Gastroenterology and Hepatology, Air force Hospital, Military Medical Academy, Cairo, Egypt
Tamer Hassan Rashwan, Lecturer of internal Medicine Departmen, Faculty of Medicine, Al-Azhar University, Assuit, Egypt;
Abdelsalam Saqr Abdelsalam, MBBcH of internal Medicine Departmen, Faculty of Medicine, Al-Azhar University, Assuit, EgyptFollow

Document Type

Original Article

Abstract

Background: Liver malignancies are a significant global health concern, ranking fifth in terms of incidence and fourth in terms of cancer-related mortality. Hepatocellular carcinoma (HCC) is the most common kind of liver cancer, accounting for around 90% of cases. Notably, the incidence of HCC has shown a substantial increase of 75% between 1990 and 2015. Aim & Objectives: To assess the outcome of thermal ablation therapy in patients with early HCC. Evaluate validation of APRI, FIB4, and Fibroscan in predicting early HCC recurrence following thermal ablation. Detect cut off point of this values in predicting early HCC recurrence following thermal ablation. Subjects & Methods: Current study was done on 50 HCC patients who undergone percutaneous TA for treatment naive HCC. Their mean age was 52-76 years with a mean of 61.5±7.41 years, 32 (64%) males and 18 (36%) females with male predominance (1:1.8 female to male ratios). Result: The Fibroscan has been identified as a highly dependable noninvasive method for evaluating liver fibrosis. However, its utilization is constrained due to its elevated cost and limited accessibility in smaller urban areas. Conclusion: The Fibroscan has been identified as a very dependable noninvasive method for evaluating liver fibrosis. However, due to its considerable expense and limited accessibility in smaller urban areas, the utilization of this tool is constrained.

Keywords

APRI; FIB4; Fibroscan; Hepatocellular Carcinoma; Thermal Ablation

Subject Area

Internal Medicine

How to Cite This Article

Al-Dahshan, Magdy Abd-Alkareem; Baki, Amin Abdel; Ramadan, Ibrahim Ghouniem; Aly, Sherif Farouk; Rashwan, Tamer Hassan; and Abdelsalam, Abdelsalam Saqr (2024) "APRI, FIB4, and Fibroscan as Predictors of early Hepatocellular Carcinoma Recurrence in patients underwent Thermal Ablation," Al-Azhar International Medical Journal: Vol. 5: Iss. 2, Article 38.
DOI: https://doi.org/10.58675/2682-339X.2269